typhoid fever
Information
- Disease name
- typhoid fever
- Disease ID
- DOID:13258
- Description
- "A primary bacterial infectious disease that is a communicable systemic illness, has_material_basis_in Salmonella enterica subsp enterica serovar Typhi, which is transmitted_by ingestion of food or water contaminated with the feces of an infected person. The infection has_symptom fever, has_symptom diarrhea, has_symptom prostration, has_symptom headache, has_symptom splenomegaly, has_symptom liver enlargement, has_symptom eruption of rose-colored spots, and has_symptom leukopenia." [url:http\://www.merriam-webster.com/medlineplus/typhoid%20fever]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04083950 | Active, not recruiting | Early Phase 1 | Induction of Gut Permeability by an Oral Vaccine | December 4, 2019 | September 30, 2024 |
| NCT00326443 | Completed | Phase 1 | CVD 909 Vi Prime Boost Study | February 2006 | August 2008 |
| NCT00342628 | Completed | Phase 2 | Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants | July 2006 | January 2011 |
| NCT00386789 | Completed | Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age | October 5, 2006 | June 17, 2008 | |
| NCT00498654 | Completed | Phase 2 | Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects | July 2007 | June 2008 |
| NCT01123941 | Completed | Phase 1 | Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) | May 2010 | November 2010 |
| NCT01193907 | Completed | Phase 2 | Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) | October 2010 | November 2010 |
| NCT01229176 | Completed | Phase 2 | Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants | March 2011 | June 2012 |
| NCT01405521 | Completed | Phase 2 | Understanding Typhoid Disease After Vaccination | October 7, 2011 | May 6, 2022 |
| NCT01421693 | Completed | Phase 4 | Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever | September 2011 | January 2015 |
| NCT01437267 | Completed | Phase 2 | Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants | October 2011 | August 2012 |
| NCT01438996 | Completed | Phase 2 | Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults | October 2011 | December 2011 |
| NCT01608815 | Completed | Phase 3 | Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects | May 2012 | December 2012 |
| NCT02192008 | Completed | N/A | Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study | December 2014 | May 26, 2022 |
| NCT02324751 | Completed | Phase 2 | Vaccines Against Salmonella Typhi | September 2015 | June 27, 2022 |
| NCT02391909 | Completed | Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers | August 26, 2015 | February 21, 2017 | |
| NCT02947295 | Completed | Global Genomic and Proteomic Profiling of African Children With Typhoid Fever | September 13, 2012 | March 1, 2017 | |
| NCT03554213 | Completed | Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India | July 2, 2018 | March 31, 2021 | |
| NCT03926455 | Completed | Phase 1 | Safety and Immunogenicity of Typhax, a Typhoid Vaccine | March 28, 2016 | February 15, 2017 |
| NCT03956524 | Completed | Phase 1 | Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults | March 16, 2019 | August 31, 2019 |
| NCT00277147 | Completed | Phase 1 | Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine | January 9, 2006 | September 17, 2008 |
| NCT04154722 | Completed | Phase 4 | Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children | June 20, 2019 | December 30, 2020 |
| NCT04801602 | Completed | Commercial Typhoid Tests Validation Trial | October 25, 2020 | December 31, 2021 | |
| NCT04830371 | Completed | Phase 2/Phase 3 | Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants | September 7, 2020 | August 1, 2021 |
| NCT05579821 | Completed | Evaluation Study of DPP® Typhoid Assay | September 15, 2022 | June 30, 2023 | |
| NCT04349826 | Recruiting | Phase 4 | The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) | May 23, 2021 | December 15, 2024 |
| NCT05500482 | Recruiting | Phase 4 | Vellore Typhoid Vaccine Impact Trial | May 1, 2023 | December 31, 2025 |
| NCT05562102 | Recruiting | TyVECO: Surveillance Protocol | August 9, 2021 | March 31, 2024 | |
| NCT04543877 | Recruiting | Early Phase 1 | WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study | September 27, 2022 | September 30, 2025 |
| NCT06104345 | Recruiting | Phase 4 | Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines | October 2023 | December 2025 |
| NCT05613205 | Recruiting | Phase 1 | Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults | December 5, 2022 | February 7, 2024 |
| NCT04852185 | Recruiting | Phase 4 | Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana | August 24, 2021 | December 31, 2024 |
| NCT05119426 | Recruiting | Phase 4 | Effectiveness of a Typhoid Conjugate Vaccine in DRC | February 11, 2022 | December 2024 |
| NCT04673487 | Unknown status | Commercial Typhoid Tests Validation | January 2021 | December 2021 | |
| NCT04235361 | Unknown status | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC | January 15, 2021 | July 30, 2021 | |
| NCT02224040 | Unknown status | Phase 4 | Typhoid Fever: Combined vs. Single Antibiotic Therapy | August 2013 | August 2015 |
- Disase is a (Disease Ontology)
- DOID:0050338
- Cross Reference ID (Disease Ontology)
- GARD:9564
- Cross Reference ID (Disease Ontology)
- ICD10CM:A01.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:002.0
- Cross Reference ID (Disease Ontology)
- MESH:D014435
- Cross Reference ID (Disease Ontology)
- NCI:C35089
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:186091002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0041466
- Exact Synonym (Disease Ontology)
- Typhoid
- ICD10 preferred id (Insert disease from ICD10)
- D0000008
- ICD10 class code (Insert disease from ICD10)
- A01.0
- MeSH unique ID (MeSH (Medical Subject Headings))
- D014435